מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
MENINGOCOCCAL GROUP C OLIGOSACCHARIDE; CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN
GLAXOSMITHKLINE INC
J07AH
MENINGOCOCCAL VACCINES
10MCG; 25MCG
SUSPENSION
MENINGOCOCCAL GROUP C OLIGOSACCHARIDE 10MCG; CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN 25MCG
INTRAMUSCULAR
0.5ML
Schedule D
TOXOIDS
Active ingredient group (AIG) number: 0243741003; AHFS:
APPROVED
2015-12-16
_ _ _Page 1 of 25_ PRODUCT MONOGRAPH MENJUGATE LIQUID 10 micrograms suspension for injection Meningococcal Group C Conjugate Vaccine House Standard Suspension for Injection Active Immunizing Agent ATC Code J07A H GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 DATE OF INITIAL APPROVAL: June 17, 2015 DATE OF REVISION: June 28, 2019 SUBMISSION CONTROL #: 226119 _ _ _©_ _2019 GSK group of companies or its licensor _ Trademarks are owned by or licensed to the GSK group of companies _PENTACEL is a trademark of Sanofi Pasteur Limited. _ _ _ _Page 2 of 25_ _ _ _Page 3 of 25_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 4 SUMMARY PRODUCT INFORMATION ....................................................................... 4 INDICATIONS AND CLINICAL USE ............................................................................. 4 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 6 DRUG INTERACTIONS ................................................................................................. 11 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ............................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 14 STORAGE AND STABILITY ......................................................................................... 14 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 14 PART II: SCIENTIFIC INFORMATION ............................................................................... 16 PHARM קרא את המסמך השלם